Higher rates of tumour-infiltrating lymphocytes (TILs) were linked to higher pCR rates in triple-negative and HER2-positive breast cancer [10] while on the other hand, PIK3CA mutations predict lower pCR rates in HER2-positive disease [11]. The gene discussed is ERBB2; the disease is neoplasm.